Regulus Therapeutics Inc.
Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
Last updated:
Abstract:
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
Status:
Application
Type:
Utility
Filling date:
25 Sep 2020
Issue date:
1 Apr 2021